The Phase III DUO trial investigated duvelisib vs. ofatumumab for chronic lymphocytic leukemia (CLL) in the relapsed/refractory setting (NCT02004522). Here, Stephan Stilgenbauer, MD, of the University of Ulm, Ulm, Germany, tells us about the final results of the trial, speaking from the European Research Initiative on CLL (ERIC) International Meeting 2018, held in Barcelona, Spain.